Abstracts Archive - Page 34 of 2425 - ACR Meeting Abstracts

Abstract Number: 0217 • ACR Convergence 2024
Understanding Treatment Goals and Factors Influencing Decisions About Clinical Trial Participation in Lupus Patients from Diverse Backgrounds
Joy Buie¹, Safoah Agyemang¹ and Joan Merrill², ¹Lupus Foundation of America, Washington, DC, ²Oklahoma Medical Research Foundation, Oklahoma City 73104, OK
Background/Purpose: With many emerging treatments in development for lupus, clinical trial recruitment has become increasingly difficult. Growing appreciation of patient input into trial design may be of …
Abstract Number: 0175 • ACR Convergence 2024
Do Knee Strength and Pain Relate to Developing Stair Climbing Difficulty for Knee Osteoarthritis?
Jason Jakiela¹, Yvonne Golightly², Sydney Liles³, Judy Foxworth⁴ and Daniel White⁵, ¹Winston-Salem State University, Winston-Salem, NC, ²University of Nebraska Medical Center, Omaha, NE, ³University of Delaware, Elkton, MD, ⁴Winston-Salem State University, Elon, NC, ⁵University of Delaware, Newark, DE
Background/Purpose: Knee osteoarthritis (OA) is a leading cause of functional limitation in older adults, and stair climbing difficulty is often the first-reported limitation. Previous work…
Abstract Number: 0196 • ACR Convergence 2024
Associations Between Systemic Lupus Erythematosus (SLE) and the Social Vulnerability Index (SVI)
Zoe Reed¹, Xana Howard¹, Cristina Arriens¹, Teresa Aberle¹, Wade DeJager², Joan Merrill³ and Judith James¹, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Oklahoma Medical Research Foundation, Oklahoma City, ³Oklahoma Medical Research Foundation, Oklahoma City 73104, OK
Background/Purpose: Systemic lupus erythematosus (SLE) is a complex autoimmune disease that disproportionately affects young women of certain racial and ethnic minority groups with enhanced severity…
Abstract Number: 0157 • ACR Convergence 2024
Knowledge and Attitudes About Delta-9-tetrahydrocannabinol (THC) Impact Real-world Practice in an International Group of Rheumatologists
Joanna Zeiger¹, Patti Katz², Mary-Ann Fitzcharles³, Stuart Kassan⁴, Teresa Simon⁵ and Kaleb Michaud⁶, ¹Canna Research Foundation, Boulder, CO, ²UCSF, San Rafael, CA, ³McGill University, Montreal-West, Canada, ⁴National Jewish Health, Denver, CO, ⁵Physicians Research Center Consultant to ForWard, Toms River, NJ, ⁶University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Rheumatologists care for difficult to manage chronic diseases, necessitating adjustments to new treatments and evolving patient views. When making treatment decisions, rheumatologists incorporate clinical…
Abstract Number: 0231 • ACR Convergence 2024
Imaging Characteristics and Demographic Variations in Patients with Axial Spondylarthritis, Axial Psoriatic Arthritis, and Inflammatory Bowel Disease-Related Arthritis with Axial Involvement: Insights from a Single Center at Cleveland Clinic Abu Dhabi
Rajaie Namas¹, Ahlam Almarzooqi², Sarah Al Qassimi³ and Esat Memisoglu³, ¹Cleveland Clinic Abu Dhabi, Detroit, MI, ²Emirates Health Services, Sharjah, United Arab Emirates, ³Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates
Background/Purpose: Spondyloarthropathies (SpAs) are a group of seronegative, inflammatory arthritides, including axial spondylarthritis (ax-SpA), axial psoriatic arthritis (ax-PsA), and inflammatory bowel disease related arthritis with…
Abstract Number: 0198 • ACR Convergence 2024
COVID-19 Vaccination and Hospitalization Rates Differ Between People with Diagnosed Immune Mediated Inflammatory Disease and the General Population: A Population-based Study
Carol Hitchon¹, Carole Taylor¹, Charles N Bernstein¹, Christine Peschken¹, J. Antonio Avina-Zubieta², Sasha Bernatsky³, Gil Kaplan⁴, Diane Lacaille², Jessica Widdifeild⁵ and RuthAnn Marrie¹, ¹University of Manitoba, Winnipeg, MB, Canada, ²Arthritis Research Canada, University of British Columbia, Vancouver, BC, Canada, ³Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ⁴University of Calgary, Calgary, AB, Canada, ⁵University of Toronto, Toronto, ON, Canada
Background/Purpose: People with immune mediated inflammatory diseases (IMIDs) are at greater risk of severe Coronavirus disease (COVID-19). Vaccination reduces COVID-19 severity however, vaccine uptake may…
Abstract Number: 0143 • ACR Convergence 2024
Behavioral Factors and Chronic Conditions Associated with Rheumatoid Arthritis, KNHANES 2010 to 2021
GI HYUN MYUNG and Juwon Lim, Seoul National University Hospital, Seoul, Republic of Korea
Background/Purpose: Rheumatoid arthritis (RA) is associated with multiple genetic and environmental factors. In terms of environmental, dietary and lifestyle factors, there have been discrepancies on…
Abstract Number: 0151 • ACR Convergence 2024
Immunoproteomic Profiling of Antibodies in Autoimmune Diseases
Choa Yun¹, Ji Qiu², M. Constanza Camargo³, Lusheng Song², Joshua LaBaer², Hyokyoung G. Hong³, Eric A. Engels³, Maddy Edie-Booker⁴, Adam Schiffenbauer⁵, Lisa Rider⁶, Frederick Miller⁷, Sarfaraz Hasni⁵, Blake M. Warner⁵, Mārcis Leja⁸ and Minkyo Song⁹, ¹National Institute on Aging, Rockville, MD, ²Arizona State University, Tempe, ³National Cancer Institute, Rockville, ⁴National Institute on Aging, Baltimore, MD, ⁵NATIONAL INSTITUTES OF HEALTH, Bethesda, MD, ⁶NIEHS, NIH, Garrett Park, MD, ⁷NIH, NIEHS, Chapel Hill, NC, ⁸University of Latvia, Rīga, Latvia, ⁹National Institutes on Aging, Baltimore, MD
Background/Purpose: Prior research has investigated a limited range of candidate markers within individual autoimmune diseases. This study aimed to identify specific and common autoantibodies and…
Abstract Number: 0229 • ACR Convergence 2024
An Early Inflammatory Cardiac Phenotype and Association with Future Coronary Plaque Burden in Rheumatoid Arthritis
Brittany Weber¹, Feng Liu², Mary Jeffway², Dana Weisenfeld², Gregory McDermott³, Elena Massarotti², Jonathan Coblyn², Michael Weinblatt⁴, Marcelo Di Carli², Damini Dey⁵ and Katherine Liao², ¹Brigham and Women's Hospital, DEDHAM, MA, ²Brigham and Women's Hospital, Boston, MA, ³Brigham and Women's Hospital, Brookline, MA, ⁴Brigham and Women's Hospital/ Harvard Medical School, Waban, MA, ⁵Cedars-Sinai Medical Center, Los Angeles
Background/Purpose: Patients with RA are at increased risk of cardiovascular disease (CVD) compared to the general population. In a prior study of RA patients with…
Abstract Number: 0216 • ACR Convergence 2024
Can Immune Checkpoint Inhibitors Safely Combat Cancer in Patients with Rheumatoid Arthritis?
Betul Ibis and Furkan Bahar, Mount Auburn Hospital/Harvard Medical School, Watertown, MA
Background/Purpose: During the past decade, antibody-based immunotherapies (including anti-PD1, anti-PD-L1, and anti-CTLA4) have revolutionized cancer treatment by enhancing the body's immune response against tumors. However,…
Abstract Number: 0233 • ACR Convergence 2024
Comparisons of Ga-FAPI and FDG PET/CT with X-ray Imaging in the Assessment of Rheumatoid Arthritis Patients
Jiana Chen¹, Dan Yang¹, Ziyue Zhou², Yaping luo³ and Huaxia Yang¹, ¹Department of Rheumatology and Clinical Immunology, National Clinical Research Center for Dermatologic and Immunologic Diseases, the Ministry of Education Key Laboratory, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, ²Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Beijing, China, ³Department of Nuclear Medicine, Chinese Academy of Medical Sciences and Peking Union Medical College Hospital, No.1 Shuaifuyuan Wangfujing, Dongcheng District, Beijing, 100730, China., Beijing, China
Background/Purpose: The imaging techniques for assessing rheumatoid arthritis (RA), including x-ray, musculoskeletal ultrasound, MRI and positron emission tomography/computed tomography (PET/CT). Fibroblast-like synoviocyte cells, which are…
Abstract Number: 0506 • ACR Convergence 2024
24-week, Post-Marketing Surveillance Analysis of Upadacitinib in Japanese Patients with Rheumatoid Arthritis: The 2024 Interim Report
Takao Fujii¹, Nami Okamoto², Asami Abe³, Michiaki Takagi⁴, Nobunori Takahashi⁵, Atsuo Nakajima⁶, Ayako Nakajima⁷, Shingo Nakayamada⁸, Keiichiro Nishida⁹, Takeshi Kawaberi¹⁰, Naomi Sunaga¹⁰, Yuki Tsujita¹¹, Sumi Chonan¹², Masataka Kuwana¹³ and Yoshiya Tanaka¹⁴, ¹Wakayama Medical University, Wakayama, Japan, ²Osaka Rosai Hospital, Sakai-city, Osaka, Japan, ³Niigata Rheumatic Center, Shibata, Japan, ⁴Yamagata University Faculty of Medicine, Yamagata, Japan, ⁵Nagoya University Graduate School of Medicine, Nagoya, Japan, ⁶Ueno Dialysis Clinic, Tokyo, Japan, ⁷Center for Rheumatic Diseases, Mie University Hospital, Mie, Japan, ⁸The First Department of Internal Medicine, University of Occupational and Environmental Health Japan,, Kitakyushu, Japan, ⁹Department of Orthopedic Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan, ¹⁰Abbvie GK, Minato-Ku, Tokyo, Japan, ¹¹AbbVie, Minato City Tokyo, Japan, ¹²Abbvie GK, Tokyo, Japan, ¹³Department of Allergy and Rheumatology, Nippon Medical School, Tokyo, Japan, Tokyo, Japan, ¹⁴Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Fukuoka, Japan
Background/Purpose: Upadacitinib (UPA) was approved in 2020 in Japan for "the treatment of Rheumatoid arthritis (RA) with inadequate response to conventional therapy (including inhibition of…
Abstract Number: 0112 • ACR Convergence 2024
Efforts to Harmonize ELISA and Non-ELISA Anticardiolipin and Anti-β2-glycoprotein-I Levels Based on ISTH SSC LA/aPL and APS ACTION International Multicenter Cohorts
Arne Vandevelde¹, Pierluigi Meroni², Hannah Cohen³, Danieli Andrade⁴, Olga Amengual⁵, TATSUYA ATSUMI⁵, Angela Tincani⁶, H Michael Belmont⁷, Maria Borghi⁸, David Branch⁹, Ricard Cervera¹⁰, Guilherme Ramires de Jesús¹¹, Paul Fortin¹², Jean-Christophe Gris¹³, Claudia Grossi⁸, Jason Knight¹⁴, Gary W. Moore¹⁵, Jacek Musiał¹⁶, Michelle Petri¹⁷, Esther Rodriguez-Almaraz¹⁸, Diana Paredes-Ruiz¹⁹, Robert Roubey²⁰, Anne Tebo²¹, Maria Tektonidou²², Denis WAHL²³, Stéphane Zuily²³, Rohan Willis²⁴, Vittorio Pengo²⁵, Maria Laura Bertolaccini²⁶, Doruk Erkan²⁷ and Katrien Devreese¹, ¹Department of Diagnostic Sciences, Ghent University and Coagulation Laboratory, Ghent University Hospital, Ghent, Belgium, ²IRCCS Istituto Auxologico Italiano 100%, Cusano Milanino, Milan, Milan, Italy, ³University College London Hospitals NHS Foundation Trust, London, United Kingdom, ⁴University of São Paulo, São Paulo, SP, Brazil, ⁵Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan, ⁶ASST Spedali Civili-University of Brescia, Brescia, Italy, ⁷NYU School of Medicine, New York, NY, ⁸Immunorheumatology research laboratory, IRCCS Istituto Auxologico, Milan, Italy, ⁹University of Utah and Intermountain Healthcare, Salt Lake City, UT, ¹⁰Hospital Clinic de Barcelona, Barcelona, Spain, ¹¹Universidade do Estado do Rio de Janeiro, Rio De Janeiro, Brazil, ¹²Centre ARThrite - CHU de Québec - Université Laval, Quebec, QC, Canada, ¹³Department of Hematology, CHU Nîmes, Univ Montpellier, Nîmes, France and Department of Hematology, Faculty of Pharmaceutical and Biological Sciences, Montpellier University, France and UMR UA11 INSERM IDESP - Montpellier University, France and Department of Obstetrics and Gynecology, I.M. Sechenov First Moscow State Medical University, Moscow, Russia, ¹⁴University of Michigan, Ann Arbor, MI, ¹⁵Specialist Haemostasis Unit, Addenbrooke's Hospital, Cambridge, United Kingdom and Department of Natural Sciences, Middlesex University, London, United Kingdom, ¹⁶Department of Internal Medicine, Jagiellonian University Medical College, Kraków, Poland, ¹⁷Johns Hopkins University School of Medicine, Timonium, MD, ¹⁸Hospital Universitario 12 de Octubre, Madrid, Spain, ¹⁹Autoimmune Diseases Research Unit. Biocruces Bizkaia Health Research Institute, Baracaldo, Spain, ²⁰Division of Rheumatology, Allergy, and Immunology, University of North Carolina, Chapel Hill, NC, ²¹Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, ²²National and Kapodistrian University of Athens, Athens, Greece, ²³Lorraine University, Nancy, France, ²⁴University of Texas Medical Branch, Galveston, TX, ²⁵Thrombosis Research Laboratory, Department of Cardio-Thoracic-Vascular Sciences and Public Health, University of Padova, Padova, Italy, ²⁶King's College London, London, United Kingdom, ²⁷Hospital for Special Surgery, New York, NY
Background/Purpose: Correlation of numerical values between the low, moderate, and high (L, M,H) levels of enzyme-linked immunosorbent assay (ELISA) and non-ELISA platforms for anticardiolipin antibody…
Abstract Number: 0123 • ACR Convergence 2024
The Impact of Sedentary Behavior and Physical Activity Level on Clinical Parameters and Quality of Life in Patients with Primary Antiphospholipid Syndrome (PAPS)
Carla Silva¹ and Danieli Andrade², ¹University of Sao Paulo, Salvador, Bahia, Brazil, ²University of São Paulo, São Paulo, SP, Brazil
Background/Purpose: PAPS is an autoimmune disease marked by thrombosis, obstetric poor outcomes and antiphospholipid antibodies. Despite treatment, APS is associated with high morbidity and mortality,…
Abstract Number: 0200 • ACR Convergence 2024
Evaluating the Effectiveness of Educational Initiatives on Recruiting Underrepresented Participants into SLE Clinical Trials
Maria Bacalao¹, Marie Maitre² and Shivani Kottur³, ¹UT Southwestern, Dallas, TX, ²Parkland Hospital, Dallas, TX, ³UT Southwestern Medical Center, Dallas, TX
Background/Purpose: Healthcare disparities in SLE clinical trials are well known, with minoritized individuals facing more significant SLE morbidity and mortality, while being underrepresented in randomized…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].